Clinical Trials Logo

Psychomotor Agitation clinical trials

View clinical trials related to Psychomotor Agitation.

Filter by:

NCT ID: NCT04061681 Completed - Multiple Sclerosis Clinical Trials

Efficacy of BIPAMS for Restless Legs Syndrome in Adults With Multiple Sclerosis: A Pilot Study

Start date: January 1, 2020
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the efficacy of a 16-week behavioral intervention for increasing physical activity and reducing restless legs syndrome (RLS) severity in persons with multiple sclerosis (MS) and RLS. The study includes a proposed sample of 20 persons with MS and RLS that will be randomized into either a 16-week behavioral intervention arm aimed at increasing physical activity or a 16-week wait-list control arm.

NCT ID: NCT04053426 Completed - Clinical trials for Agitation,Psychomotor

Agitation Follow up After Introduction of a New Patient Care Algorithm

SARA
Start date: July 19, 2018
Phase:
Study type: Observational

Agitation in the intensive care unit is motor hyperactivity. It is frequent (b/w 30% to 70%) and has multiple causes: pain, medical reason, delirium, medication, etc. It can be a source of complication, for the patient, and equipment pullout. International recommendations state that the agitation should be taken care of with standardized protocols to improve patient care.

NCT ID: NCT04018157 Completed - Clinical trials for Agitation, Emergence

Single Bolus Dose of Ketodex Versus Ketofol For Prevention Of Emergence Agitation In Adults Undergoing Nasal Surgeries

Start date: July 3, 2019
Phase: Early Phase 1
Study type: Interventional

- emergence agitation is seen in around 68% after nasal surgeries. Agitated patients needs more staff and nurses to control their abnormal movement which leads to self extubation , removal of catheters and bruises in the extremities. - Dexmedetomidine, ketamine, propofol intravenous infusion and other agents was used to prevent EA . Recently, ketodex is found to reduce the incidence and severity of EA . - We aim to compare single bolus dose of Ketodex Versus Ketofol For Prevention Of emergence Agitation in adults undergoing nasal surgeries.

NCT ID: NCT04010305 Completed - Schizophrenia Clinical Trials

Sub-Lingual Dexmedetomidine in Agitation Associated With Schizophrenia

Start date: May 22, 2019
Phase: Phase 1
Study type: Interventional

This is a two-stage adaptive Phase Ib trial design, that will identify two doses (lowest dose with clinical benefit and highest safe dose) in a first stage and better evaluate safety, tolerability and variability of effect in the second stage.

NCT ID: NCT03862391 Completed - Clinical trials for Agitated; State, Acute Reaction to Stress

Does Low Flow Anesthesia Reduce Postanaesthetic Emergence Agitation?

Start date: June 1, 2018
Phase: Phase 4
Study type: Interventional

In this study, the investigators aimed to compare postanesthetic agitation in patients undergoing laparotomic gynecological surgery under general anesthesia using sevoflurane at a fresh gas flow rate of 2 L / min with fresh gas flow rate of 0.5 L / min.

NCT ID: NCT03818243 Completed - Parkinson Disease Clinical Trials

Circadian Character of Food Compulsions and Impulses Control Disorders in Parkinsonian Patients With and Without Resting Leg Syndrome

RLS nighfood
Start date: January 21, 2019
Phase: N/A
Study type: Interventional

Investigator have recently shown that Parkinson disease patients' with restless leg Syndrome have more frequent impulse control behavior in particular compulsive feeding that patients without Restless Leg Syndrome (RLS). Investigator hypothesized that presence of RLS in parkinsonian patients could be a risk factor for the emergence of TCI or associated behaviors, occurring preferentially at night. The main objective of this study is to evaluate in patients with idiopathic Parkinson's disease (IPD) the effect of the presence of a RLS on the evening compulsive eating behavior by studying the circadian modulation of food intake of patients with RLS and impulse control disorders. For this investigator conduct a prospective study, with 2 groups of Parkinson disease patients (with and without restless leg syndrome), to which investigator have to fill an agenda to know the schedule of the behaviors during the day and the night.

NCT ID: NCT03807011 Completed - Emergence Agitation Clinical Trials

Emergence Agitation in Pediatric Strabismus Surgery

Start date: July 7, 2017
Phase: N/A
Study type: Interventional

This study was performed to assess the effects of continuous remifentanil infusion and single bolus administration of fentanyl on the incidence of emergence agitation in pediatrics undergoing strabismus surgery.

NCT ID: NCT03806530 Completed - Clinical trials for End Stage Renal Disease

DIalysis Symptom COntrol-Restless Legs Syndrome Trial

DISCO-RLS
Start date: May 1, 2019
Phase: Phase 3
Study type: Interventional

The DISCO-RLS Trial is a randomized controlled trial to determine the safety and efficacy of pharmacologic therapy (ropinirole versus placebo and gabapentin versus placebo) for the treatment of Restless Legs Syndrome in patients with End Stage Renal Disease requiring hemodialysis.

NCT ID: NCT03724942 Completed - Clinical trials for Agitation Associated With Dementia of the Alzheimer's Type

Brexpiprazole for the Long-term Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type

Start date: November 9, 2018
Phase: Phase 3
Study type: Interventional

To evaluate the safety of brexpiprazole 1 mg or 2 mg after a 14 week treatment regimen for agitation associated with dementia of the Alzheimer's type patients who completed in a double-blind trial, and to investigate the efficacy of brexpiprazole.

NCT ID: NCT03710642 Completed - Alzheimer's Disease Clinical Trials

Prazosin for Agitation in Alzheimer's Disease

Start date: October 23, 2018
Phase: Phase 2
Study type: Interventional

The study evaluates the effects of Prazosin on agitation in adults with Alzheimer's disease. Two thirds of the participants will participate in the medication portion, while one third will participate in the placebo portion